This educational webinar was sponsored and directed by Bristol Myers Squibb.
Watch our latest webinar on-demand now, exploring the ways in which clinical decision making is affected by long term outcomes in clinical trials. Chair of this webinar series, Guillermo de Velasco, University Hospital October 12, Madrid, Spain, and guest presenter Meredith Regan, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA, analyse various patient cases in order to understand how useful overall survival is as an endpoint in Phase III trials. The European Medicines Agency (EMA) and the Food and Drug Administration (FDA) guidelines for the approval of cancer drugs are then explored.
Discussion later focuses on an analysis of the potential challenges of using overall survival, before going on to explore the uses of different clinical trial analyses and endpoints. The talk concludes with a look into how long-term safety information can shape patient care. Watch now for a deep dive into clinical trials and to stay on the cutting edge of this field!
Biographies:
Guillermo de Velasco
Guillermo de Velasco is a renowned medical oncologist whose clinical and research interests include genitourinary tumours, melanomas, and early-stage studies. His profound expertise played an integral role in shaping the ESMO guidelines for managing renal cell carcinoma. De Velasco’s exceptional contributions have positioned him as a cornerstone in advancing the understanding and treatment of these diseases, solidifying his substantial impact within the medical field.
Meredith Regan
Meredith Regan is a distinguished Professor in the Division of Biostatistics, Dana-Farber Cancer Institute, USA, and Professor of Medicine, Harvard Medical School, USA. She is developing a novel endpoint, treatment-free survival, with an integrated analysis approach to characterise the antitumor activity and adverse effects of immunotherapy regimens for advanced solid tumours.
